Venlafaxine and asthma.
A 54-year-old man of Asian origin with major depression developed an asthma-like reaction during venlafaxine treatment. Two weeks after therapy was initiated, he experienced gradually worsening dry cough at night and periodically dyspnea during the daytime. After 5 weeks, clinical examination revealed marked signs of pulmonary obstruction and the forced expiratory volume (FEV1) was assessed to only 32% of the expected value. The venlafaxine medication was gradually decreased and eventually discontinued 9 weeks after its initiation, resulting in a successive improvement of the patient's respiratory complaints.
Melien
Øyvind
Ø
Section of Clinical Pharmacology, Rikshospitalet University Hospital, NO-0407, Oslo, Norway. oyvind.melien@rikshospitalet.no
Skaali
Tone
T
Myhr
Kirsten
K
Brørs
Odd
O
D001249:Asthma / Q000139:chemically induced*; D003511:Cyclohexanols / Q000009:adverse effects*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D008297:Male; D008875:Middle Aged; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D000069470:Venlafaxine Hydrochloride
D003511:Cyclohexanols; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride